Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.71 |
| ▸ | HSP90AA1 | P07900 | 12/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.62 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.62 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366455 | 1.00 | HSP90AB1 (0.71) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL28932207 | 0.89 | HSP90AB1 (0.61) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL3395507 | 0.89 | HSP90AB1 (0.74) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL3394076 | 0.87 | HSP90AB1 (0.68) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL3821565 | 0.87 | YTHDC1 (0.57) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL29366555 | 0.86 | HSP90AA1 (0.54) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL14441142 | 0.86 | HSP90AB1 (0.54) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL5471657 | 0.86 | HSP90AA1 (0.54) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 | |
| SCHEMBL3392226 | 0.85 | HSP90AB1 (0.77) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL21977307 | 0.85 | HDAC6 (0.69) | HSP90AB1HSP90AA1ADORA2AHDAC6HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021027594-A1 | IMIDAZOLOPYRIMIDINE COMPOUNDS COMPRISING FUSED RING GROUP, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-8026245-B2 | HIV replication inhibiting purine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-27 | — | — | US | disclosed |
| US-8026245-B2 | HIV replication inhibiting purine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-09-27 | — | — | US | disclosed |
| EP-1668011-B1 | HIV REPLICATION INHIBITING PURINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-02 | — | — | EP | disclosed |
| EP-2145888-A1 | Deazapurine derivatives as HSP90-Inhibitors | Conforma Therapeutics Corporation (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070203159-A1 | Purine compounds | UNIVERSITETET I OLSO (NO) | 2007-08-30 | — | — | US | disclosed |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2007-08-09 | — | — | US | disclosed |
| US-7138401-B2 | 2-aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1670802-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | Conforma Therapeutic Corporation (US) | 2006-06-21 | — | — | EP | disclosed |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | CONFORMA THERAPEUTICS CORPORATION | 2005-05-26 | — | — | US | disclosed |
| WO-2005028434-A2 | NOVEL HETEROCYCLIC COMPOUNDS AS HSP90-INHIBITORS | CONFORMA THERAPEUTICS CORPORATION (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203159-A1 | Purine compounds | PNP, UMPS, TYMP | HSP90AB1 3579/4885HSP90AA1 4068/4885ADORA2A 96/4885 |
| US-20050113340-A1 | 2-Aminopurine analogs having HSP90-inhibiting activity | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885ADORA2A 1896/4885 |
| US-20070185064-A1 | 2-Aminopurine Analogs Having HSP90-Inhibiting Activity | HSP90AB2P, HSP90AB1, HSP90AA1 | HSP90AB1 2/4885HSP90AA1 3/4885ADORA2A 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.